Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combo Products Guidance Could Help Point Novel OTC Switches In Right Direction

This article was originally published in The Tan Sheet

Executive Summary

FDA delivers a draft GMPs guidance for combination products, providing details and examples on how the agency regulates drug delivery devices and other drug/device products. The document could be useful for firms interested in proposing novel Rx-to-OTC switches.

You may also be interested in...



FDA Draft Guidance Points Upward For OTC Wellness Device Development

The decision algorithm and flexible approach in a draft guidance on general wellness products will support innovative mobile health development, an industry advocate says. FDA does not intend to review low-risk OTC products, such as exercise equipment, that claim to support various facets of patients' wellness.

FDA Draft Guidance Points Upward For OTC Wellness Device Development

The decision algorithm and flexible approach in a draft guidance on general wellness products will support innovative mobile health development, an industry advocate says. FDA does not intend to review low-risk OTC products, such as exercise equipment, that claim to support various facets of patients' wellness.

Industry Seeks More Clarity Following Combo Product GMP Final Rule

FDA’s final regulation outlines which manufacturing system requirements apply to products that have drug, device and/or biologic components. An industry coalition says key details need to be filled in by FDA with guidance.

Related Content

Topics

UsernamePublicRestriction

Register

PS107510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel